Citations

Showing 10 of 108135 citations.

Pooled subgroup analysis of twelve randomized controlled trials of immunotherapy in non-small cell lung cancer.
Adjei, Alex A. , Leventakos, Konstantinos , Li, Rutian , Wang, Lifeng , Liu, Baorui , Molina, Julian R. , Yang, Fang , Wang, Yucai , Mansfield, Aaron S. , Wei, Jia

Mayo Clinic

Journal of Clinical Oncology | May 28, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e20639-e20639

10.1200/jco.2019.37.15_suppl.e20639 Get It

e20639 Background: Multiple randomized controlled trials (RCTs) have shown a robust benefit of immunotherapy with immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). We did a meta-analysis to examine the benefit of ICI in various subgroups. Methods: PubMed was searched up to Jan 15, 2019 for RCTs comparing overall survival (OS) between ICI and control (without ICI) arms. Pooled hazard ratio (HR) and 95% confidence interval (CI) was calculated for each subgroup. Interaction tests were done to compare relative benefit between opposed subgroups of interest (eg. men vs women; reported as Pheterogeneity). All analyses were performed with a random effects model in Comprehensive Meta Analysis (v2). Results: Twelve phase 2/3 RCTs involving 7244 patients were included. A significant OS benefit of ICI was found in both squamous and non-squamous histology. Current/former smokers, EGFR wild-type, and KRAS mutant patients had a significant OS benefit from ICI, but never smokers, EGFR mutant, and KRAS wild-type patients did not. An OS benefit of ICI was found in patients with or without baseline brain metastasis, PD-L1 < 1% or ≥1%, men or women, age < 65 or ≥65, and ECOG PS 0 or ≥1. No significant difference of relative benefit from ICI over control was found in patients with different PD-L1 expression, sex, age, or ECOG PS (Table). Conclusions: OS benefit of ICI in NSCLC was associated with a smoking history, wild-type EGFR or KRAS mutation. However, the OS benefit of ICI was seen regardless of histology, PD-L1 expression, sex, age, and ECOG PS. [Table: see text]
Clinical predictors of efficacy for immune checkpoint inhibition in lung cancer patients.
Zhang, Shijia , Pease, Daniel F. , Joshi, Shilvi P, Wang, Yucai , Patel, Manish R.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e20600-e20600

10.1200/jco.2019.37.15_suppl.e20600 Get It

e20600 Background: Immune checkpoint inhibitors (ICIs) have changed the treatment paradigm of advanced NSCLC and SCLC. The populations in clinical trials generally were composed of patients (pts) with excellent performance status (PS), a minimal number of prior lines of therapy, and no history of (h/o) autoimmune disease (AD). The aim of this retrospective study was to investigate the predictors of survival in less fit and more heavily pretreated lung cancer pts at our institution. Methods: Medical records of lung cancer pts who started single-agent ICI from 2015 to 2018 were reviewed for data collection. Progression-free survival (PFS) and overall survival (OS) were compared by age, PS, smoking, PD-L1 expression, brain metastasis, prior lines of systemic therapy, h/o AD, and immune-related adverse events (irAE). Results: We included 150 pts who received at least 1 dose of nivolumab, pembrolizumab, or atezolizumab (median age 66, range 36-92, 56% female, 89% NSCLC, 97% stage 4, 13% never smoker, 34% ECOG ≥ 2, 37% ≥ 2 prior lines of therapy, 29% developed irAE). The overall response rate was 30% and clinical benefit rate 51% (3% CR, 27% PR, 21% SD). The median PFS was 3.7 months (m) overall and 12.3 m for those with ≥ 4 cycles of therapy. The median OS was 12.4 m overall and 26.0 m for those with ≥ 4 cycles. The median PFS and OS were not significantly different by age, PS, smoking, PD-L1, brain metastasis, prior lines of therapy, or h/o AD. The median OS was longer for pts with ECOG 0-1 than those ≥ 2 (14.6 vs 7.5 m, p < .001). The median PFS and OS for pts with irAE were longer compared to those without irAE (12.3 vs 2.6 m, p < .001 for PFS and 28.9 vs 9.1 m, p = .001 for OS). Multiple Cox regression analysis identified ECOG 0-1 (HR 0.54, p = .007) and irAE (HR 0.48, p = .003) to be independently associated with improved OS. 27 pts (18%) required steroids for irAE. There were no treatment-related deaths. Of 11 pts with h/o AD, only 1 experienced disease flare. Conclusions: The clinical benefit of ICIs persists in older or heavily pretreated pts. ECOG 0-1 and incident irAE predicted for improved survival. Survival for pts with ECOG ≥ 2 is very limited, suggesting ICIs should be used judiciously in this group. Therapy was well tolerated, with a low risk for flare of previous autoimmune disease.
Faculty Opinions recommendation of Mesenchymal stromal cells are required for regeneration and homeostatic maintenance of skeletal muscle.
LeBrasseur, Nathan K.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | May 28, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735757106.793560453 Get It

Adalimumab‐induced erythrodermic reactions
Nowsheen, Somaira , Kohorst, John J. , El-Azhary, Rokea A, el‐Azhary, Rokea A.

Mayo Clinic

International Journal of Dermatology | May 28, 2019 | Volume: 58 | Issue: 10 | Pages: No page available

10.1111/ijd.14503 | PMID 31135963 Get It

Reply
Duarte‐García, Alí , Crowson, Cynthia S. , Warrington, Kenneth J. , Matteson, Eric L. , Duarte-García, Alí , Warrington, Kenneth J

Mayo Clinic

Arthritis & Rheumatology | May 28, 2019 | Volume: 71 | Issue: 10 | Pages: 1769-1770

10.1002/art.41000 | PMID 31135097 Get It

Teaching Video NeuroImages: Foix-Chavany-Marie syndrome
Mantyh, William G. , Chandregowda, Adithya , Fulgham, Jimmy R., Flemming, Kelly D. , Laughlin, Ruple S. , Flemming, Kelly D , Jones, David T.

Mayo Clinic

Neurology | May 28, 2019 | Volume: 92 | Issue: 22 | Pages: No page available

10.1212/wnl.0000000000007569 | PMID 31133571 Get It

Mystery Case: Missed diagnosis of hereditary hemorrhagic telangiectasia presenting with recurrent ischemia
Brinjikji, Waleed , Wood, Christopher P. , Iyer, Vivek

Mayo Clinic

Neurology | May 28, 2019 | Volume: 92 | Issue: 22 | Pages: 1068-1069

10.1212/wnl.0000000000007568 | PMID 31133563 Get It

Outcomes Following Transoral Laser Microsurgery With Resection of Cartilage for Laryngeal Cancer
Chang, Brent A. , Nagel, Thomas H. , Howard, Brittany E. , Hayden, Richard E. , Hinni, Michael L., Chang, Brent A , Lott, David G.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | May 28, 2019 | Volume: 128 | Issue: 10 | Pages: 978-982

10.1177/0003489419851521 | PMID 31132856 Get It

Introduction: The ability to treat more advanced laryngeal cancers by transoral approaches has expanded significantly in the past several decades. Transoral management of laryngeal cancers that require removal of the laryngeal framework is controversial. Resecting cartilage through endoscopic means carries inherent technical challenges and the question of oncologic safety. Methods: We describe a retrospective review of patients undergoing resection of the thyroid cartilage during transoral laser microsurgery (TLM) for laryngeal cancer over a 10-year period. Only patients with 5-year follow-up were included. Results: Fourteen patients were identified that underwent attempted endoscopic resection of the thyroid cartilage. Preoperative staging ranged from T1 to T4 laryngeal cancers. Most patients underwent resection of the thyroid cartilage either for close proximity of the tumor to cartilage or microscopic involvement of the inner perichondrium, although 6 patients had gross invasion of the cartilage. Twelve patients underwent successful endoscopic clearance. Two patients were converted to total laryngectomy either at the time of surgery or shortly after due to extent of disease that was deemed not amenable to endoscopic resection. Overall 5-year survival was 71%. Disease-free survival was 62% at 5 years. The majority of patients avoided gastrostomy and tracheostomy tube dependence. One patient underwent total laryngectomy following initial TLM for chronic aspiration. Conclusion: We conclude that TLM for laryngeal cancer performed with removal of thyroid cartilage is feasible. Both oncologic and functional outcomes are reasonable in a select group of patients. This paper describes that cartilage can be resected endoscopically in the appropriate setting and not necessarily that cartilage invasion should routinely be treated with TLM.
Attitudes of Hospice Providers Regarding Intrathecal Targeted Drug Delivery for Patients With Cancer
Warner, Lindsay L. , Moeschler, Susan S., Strand, Jacob J. , Strand, Jacob J , Pittelkow, Thomas P.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | May 28, 2019 | Volume: 36 | Issue: 11 | Pages: 955-958

10.1177/1049909119852928 | PMID 31132860 Get It

Pain is one of the most commonly experienced and feared symptoms faced by patients with a serious illness. For these patients, intrathecal drug delivery systems (IDDSs) provide greater potency and/or few systemic side effects. However, despite these benefits, the integration and management of IDDS for patients receiving hospice care has not been previous studied. An electronic, 18-question survey was sent to 200 hospice practitioners (physicians, nurse practitioners and nurses) in the state of Minnesota to explore their experience, confidence, and the perceived barriers to caring for patients with IDDS while being cared for on hospice. Providers were identified though mailing lists from the Minnesota Network of Hospice and Palliative Care organization. The survey was administered by the Mayo Clinic Survey Research Center with institutional review board approval. Slightly more than 50% of respondents have ever cared for a patient with an intrathecal pump. If a patient had a pump in place, only 28% of providers expressed confidence in managing their pain. Additionally, only 3 of 10 respondents felt that adjusting an intrathecal pump should be the first option when a patient with an IDDS in place had increased pain. Indeed, the vast majority (over 80%) of respondents preferred the use of systemic therapies for primary pain management. Access to IDDS vendors for changes/refills in the home is identified as another barrier with over 50% of respondents either unaware of an available vendor or reporting no vendor available. There are numerous self-reported barriers to ongoing use of IDDS with patients receiving hospice care.